SCHEMBL2717795

SCHEMBL2717795

CC1OC1COCCOc1ccc(-c2ccc(-c3ccc(OCCOCC4OC4C)cc3)cc2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RARB P10826 2/20 0.41
CYP2D6 P10635 5/20 0.39
CYP3A4 P08684 4/20 0.39
HRH3 Q9Y5N1 6/20 0.38
HRH2 P25021 4/20 0.38
HRH1 P35367 4/20 0.38
LSS P48449 1/20 0.37
RARA P10276 1/20 0.36
CYP19A1 P11511 3/20 0.36
CYP2C9 P11712 3/20 0.36
CYP2C19 P33261 3/20 0.36
CYP1A2 P05177 2/20 0.36
ABCB1 P08183 2/20 0.35
ABCC1 P33527 1/20 0.35
ABCG2 Q9UNQ0 1/20 0.35
CHRNB2 P17787 1/20 0.35
CHRNB4 P30926 1/20 0.35
CHRNA3 P32297 1/20 0.35
CHRNA7 P36544 1/20 0.35
CHRNA4 P43681 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2720240 0.86 PPARG (0.40) RARBRARAABCB1ABCC1ABCG2
SCHEMBL2829748 0.83 TP53 (0.37) CYP2D6CYP3A4HRH3HRH2HRH1
SCHEMBL2719083 0.83 RAB9A (0.41) CYP3A4HRH3CYP2C9SMN1; SMN2
SCHEMBL2825828 0.78 HRH3 (0.33) RARBHRH3HRH2HRH1
SCHEMBL2830474 0.77 SMN1; SMN2 (0.30) SMN1; SMN2
SCHEMBL12251751 0.76 MEN1 (0.48) HRH3CYP1A2ALDH1A1TP53MAPT
SCHEMBL2719932 0.74 TDP1 (0.50) RARBCYP3A4HRH3HRH2HRH1
SCHEMBL2829822 0.74 TDP1 (0.50) RARBCYP3A4HRH3HRH2HRH1
SCHEMBL15993655 0.73 ALDH1A1 (0.55) CYP3A4HRH3HRH2HRH1CYP1A2
SCHEMBL4059613 0.71 RARB (0.53) RARBCYP2D6CYP3A4LSSRARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1995245-B1 METHOD FOR PRODUCING EPOXY COMPOUND SUMITOMO CHEMICAL CO (JP) 2012-05-02 EP disclosed
US-20100144926-A1 EPOXY RESIN COMPOSITION SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-06-10 US disclosed
EP-2133379-A1 EPOXY RESIN COMPOSITION Sumitomo Chemical Company, Limited (JP) 2009-12-16 EP disclosed
EP-2133380-A1 RESIN COMPOSITION Sumitomo Chemical Company, Limited (JP) 2009-12-16 EP disclosed
US-20090054669-A1 Process For Producing Epoxy Compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-02-26 US disclosed
US-20090018355-A1 Process for Crystallizing an Epoxy Compound SUMITOMO CHEMICAL COMPANY, LTD. 2009-01-15 US disclosed
EP-1995245-A1 METHOD FOR PRODUCING EPOXY COMPOUND Sumitomo Chemical Company, Limited (JP) 2008-11-26 EP disclosed
EP-1995244-A1 METHOD FOR CRYSTALLIZATION OF EPOXY COMPOUND Sumitomo Chemical Company, Limited (JP) 2008-11-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018355-A1 Process for Crystallizing an Epoxy Compound PTGER1, NR5A1, TCP1 RARB 1877/4885CYP2D6 1016/4885CYP3A4 470/4885
US-20090054669-A1 Process For Producing Epoxy Compound RER1, AR, CYP1A1 RARB 1762/4885CYP2D6 355/4885CYP3A4 318/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.